SenegalTuberculosis profile
Population  2018 16 million
Estimates of TB burdenº, 2018 Number (thousands) Rate
(per 100 000 population)
Total TB incidence 19 (13–25) 118 (84–158)
HIV-positive TB incidence 0.91 (0.64–1.2) 5.7 (4–7.7)
MDR/RR-TB incidenceºº 0.24 (0.095–0.44) 1.5 (0.6–2.8)
HIV-negative TB mortality 2.6 (1.7–3.8) 17 (10–24)
HIV-positive TB mortality 0.25 (0.17–0.34) 1.6 (1.1–2.2)
Estimated proportion of TB cases with MDR/RR-TB, 2018
New cases 0.9%
Previously treated cases 6.2% (4.8–7.9)
TB case notifications, 2018  
Total new and relapse 13 250
          - % tested with rapid diagnostics at time of diagnosis 14%
          - % with known HIV status 90%
          - % pulmonary 88%
          - % bacteriologically confirmedººº 89%
          - % children aged 0-14 years 5%
          - % women 29%
          - % men 66%
Total cases notified 13 663
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2018 71% (53–99)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2018 16% (9–24)
TB/HIV care in new and relapse TB patients, 2018 Number (%)
Patients with known HIV status who are HIV-positive 592 5%
          - on antiretroviral therapy 553 93%
Drug-resistant TB care, 2018
% of bacteriologically confirmed TB cases tested for rifampicin resistance ººº
          - New cases 15%
          - Previously treated cases 67%
Laboratory-confirmed cases* MDR/RR-TB: 97, XDR-TB: 0
Patients started on treatment* ** MDR/RR-TB: 88, XDR-TB: 0
MDR/RR-TB cases tested for resistance to second-line drugs 9
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2017 87% 13 235
Previously treated cases, excluding relapse, registered in 2017 64% 302
HIV-positive TB cases registered in 2017 56% 749
MDR/RR-TB cases started on second-line treatment in 2016 93% 54
XDR-TB cases started on second-line treatment in 2016   0
TB preventive treatment, 2018  
% of HIV-positive people (newly enrolled in care) on preventive treatment 10%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
36% (33–39)
TB financing, 2019  
National TB budget (US$ millions) 14
Funding source: 13% domestic, 18% international, 69% unfunded
º Ranges represent uncertainty intervals
ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Incidence graph
   Total TB incidence
   New and relapse TB cases notified
   HIV-positive TB incidence

(Rate per 100 000 population per year)
Mortality graph
   HIV-negative TB mortality

Notified cases by age group and sex, 2018
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2019-10-21 Data: www.who.int/tb/data